Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression.
Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression.
复制标题
Covid-19对肠易激综合症和合并焦虑和/或抑郁症患者的影响。
DOI：
10.1097/mcg.0000000000001515
复制
发表时间：
2022-02-01
影响因子：
2.9
通讯作者：
Heitkemper MM
中科院分区：
文献类型：
--
作者：
Kamp KJ;Levy RL;Munson SA;Heitkemper MM
本研究的目的是描述COVID-19大流行对参与活动能力的影响，以及对肠易激综合征（IBS）和共病焦虑和/或抑郁患者的心理困扰和胃肠道症状的影响。与单独患有IBS的个体相比，患有IBS和共病焦虑和/或抑郁的个体报告症状增加，生活质量下降。当前的COVID-19大流行有可能进一步影响IBS和共病焦虑和/或抑郁个体的症状，符合IBS-IV标准并报告轻度至重度焦虑和/或抑郁的个体被纳入。参与者完成了一项在线调查，问题涉及焦虑，抑郁，COVID对活动和症状的影响以及人口统计学。55人参加了这项研究。COVID-19大流行最普遍地影响了他们与朋友和家人共度时光、购买某些类型的食品以及获得医疗保健的能力。参与者还报告了压力增加（92%），焦虑（81%）和抑郁症状（67%）。最后，大约一半的样本报告腹痛（48%），腹泻（45%）或便秘（44%）增加。2019冠状病毒病大流行与IBS和共病焦虑和/或抑郁个体自我报告的心理困扰和胃肠道症状增加有关。需要更多的研究来干预这些症状。
The goal of this study was to describe the influence of the COVID-19 pandemic on ability to engage in activities and the influence on psychological distress and gastrointestinal symptoms among individuals with irritable bowel syndrome (IBS) and comorbid anxiety and/or depression. Individuals with IBS and comorbid anxiety and/or depression report increased symptoms and decreased quality of life compared to individuals with IBS alone. The current COVID-19 pandemic has the potential to further influence symptoms among individuals with IBS and comorbid anxiety and/or depression Individuals who met the Rome-IV IBS criteria and reported mild to severe anxiety and/or depression were included. Participants completed an online survey with questions about anxiety, depression, impact of COVID on activities and symptoms, and demographics. Fifty-five individuals participated in the study. The COVID-19 pandemic most commonly influenced their ability to spend time with friends and family, shop for certain types of food, and access healthcare. Participants also reported increased stress (92%), anxiety (81%), and depressive symptoms (67%). Finally, around half the sample reported increases in abdominal pain (48%), diarrhea (45%), or constipation (44%). The COVID-19 pandemic is related to self-reported increases in psychological distress and gastrointestinal symptoms among individuals with IBS and comorbid anxiety and/or depression. Additional research is needed to intervene on these symptoms.